Table 2. Epidemiological changes in characteristics of infants aged <6 months.
| 2018–2020 (n = 216) | 2021 (n = 117) | P-value | |
|---|---|---|---|
| Sex: male, n (%) | 117 (54.2) | 59 (50.4) | 0.566 |
| Palivizumab indication, n (%) | 8 (3.7) | 1 (0.9) | 0.168 |
| not indicated | 208 (96.3) | 116 (99.1) | |
| Palivizumab prophylaxis, n (%) | 6 (2.8) | 0 (0) | 0.0944 |
| not administered | 210 (97.2) | 117 (100.0) | |
| Presence of siblings, n (%) | 160 (74.1) | 110 (94.0) | 0.00256 |
| no siblings | 20 (9.3) | 2 (1.7) | |
| unknown | 36 (16.7) | 5 (4.3) | |
| Hospitalization duration | |||
| mean days (SD) | 6.05 (2.38) | 6.37 (2.98) | 0.316 |
| Oxygen use rate, n (%) | 100 (46.3) | 63 (53.8) | 0.207 |
| HFNC use rate, n (%) | 36 (16.7) | 31 (26.5) | 0.0444 |
| Ventilator use rate, n (%) | 3 (1.4) | 2 (1.7) | 1 |
| Mortality rate, n (%) | 0 (0) | 0 (0) | NA |
HFNC, high-flow nasal cannula; SD, standard deviation